Feed / KYTX

Kyverna Therapeutics, Inc.

KYTX

Healthcare · 8.74 +12.6% today

Participation confirmed · construction unavailableMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

Kyverna Therapeutics, Inc.'s move is being confirmed by its market group.

No new filing conclusion is available. 21 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Company+12.6% todayVolume comparison unavailable
Market group21 of 21 activeOncology and Gastrointestinal Biotech · active
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 14 of 21 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as CBLL begins moving with the group.

Invalidation: The live read weakens if participation falls to 7 of 21 members or fewer.

Watch this read

Who this business touches

The relationships behind KYTX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

NTLAIntellia Therapeutics, Inc.partnerMay 12, 2026

In December 2021, we entered into a License and Collaboration Agreement, or the Intellia Agreement, with Intellia Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics leveraging CRISPR-based technologies, or Inte…

CRSPCRISPR Therapeutics AGcompetitorMay 12, 2026

During the term of the Co-Co Agreement, subject to certain exceptions, neither party will clinically develop or commercialize a cell therapy product directed to CD19 other than the CRISPR Product for use in the treatment or prevention of certain indications s…

Depended on by

IMMXImmix Biopharma, Inc.competitorMar 25, 2026

In addition, we face competition from companies developing cell therapies for immune-mediated disease, some of which include Kyverna Therapeutics, Inc.; Cabaletta Bio, Inc.; Fate Therapeutics Inc.; and Arcellx, Inc.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

KYTX is currently a Early Follower in the organic co-movement group Oncology and Gastrointestinal Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.